Tumour-necrosis-factor antibody treatment in Crohn's disease

The Lancet

Volumn 342, Issue 8864, 1993, Pages 173-174

  Derkx, Bert ^a   Taminiau, Jan ^a   Radema, Sandra ^a   Stronkhorst, Arnold ^a   Wortel, Cees ^a   Tytgat, Guido ^a   van Deventer, Sander ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BECLOMETASONE; MESALAZINE; METRONIDAZOLE; MONOCLONAL ANTIBODY; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; CASE REPORT; CROHN DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; PRIORITY JOURNAL; SCHOOL CHILD;

AMINOSALICYLIC ACIDS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CASE REPORT; CHILD; CROHN DISEASE; FEMALE; HUMAN; MESALAMINE; PREDNISONE; TUMOR NECROSIS FACTOR;

EID: 0027231774     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)91375-V     Document Type: Letter

References (4)

1. Enhanced mucosal cytokine production in inflammatory bowel disease
2. Increased production of interleukin-1α, interleukin-2 and soluble interleukin-2 receptor in endoscopic mucosal biopsy specimens with active inflammatory bowel disease
3. Serum concentrations of tumour necrosis factor-α in childhood chronic inflammatory bowel disease
4. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation